TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36338374

Group type: EXPERIMENTAL
Intervention: Simple crossover alone
Number of subjects: 2194

Group type: COMPARATOR
Intervention: SB-opening procedure
Number of subjects: 2194

Group type: EXPERIMENTAL
Intervention: Simple crossover alone (LM subgroup)
Number of subjects: 2194

Group type: COMPARATOR
Intervention: SB-opening procedure (LM subgroup)
Number of subjects: 2194

Group type: EXPERIMENTAL
Intervention: Simple crossover alone (true bifurcation subgroup)
Number of subjects: 2194

Group type: COMPARATOR
Intervention: SB-opening procedure (true bifurcation subgroup)
Number of subjects: 2194
Study: 36338402

Group type: EXPERIMENTAL
Intervention: Transcatheter edge-to-edge repair (TEER) using a novel device for severe MR
Number of subjects: 23
Study: 36338409

Group type: EXPERIMENTAL
Intervention: Serial CCTA
Number of subjects: 830
Study: 36338415

Group type: EXPERIMENTAL
Intervention: Residual Inflammatory Risk (RIR) determined by high-sensitivity C-reactive protein (hsCRP) measurements
Number of subjects: 4562

Group type: EXPERIMENTAL
Intervention: Persistent high RIR (hsCRP ≥2 mg/L)
Number of subjects: 4562
Study: 36338481

Group type: EXPERIMENTAL
Intervention: 7% solution of xylitol
Number of subjects: 0

Group type: COMPARATOR
Intervention: 7% solution of free sugars (glucose, fructose, sucrose)
Number of subjects: 0
Study: 36338546

Group type: EXPERIMENTAL
Intervention: Combined inhibition of DDK and WEE1
Number of subjects: 0

Group type: COMPARATOR
Intervention: DDK inhibitor
Number of subjects: 0

Group type: COMPARATOR
Intervention: WEE1 inhibitor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inhibition of CDK1 or microtubule polymerization
Number of subjects: 0
Study: 36338743

Group type: EXPERIMENTAL
Intervention: Third dose (booster) of COVID-19 mRNA vaccination (Pfizer-BioNTech or Moderna)
Number of subjects: 320

Group type: COMPARATOR
Intervention: First two doses of COVID-19 mRNA vaccination
Number of subjects: 320
Study: 36339063

Group type: EXPERIMENTAL
Intervention: CT coronary angiography (CTCA) for quantitative plaque characterization
Number of subjects: 327
Study: 36339117

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 1096

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1096
Study: 36339122

Group type: EXPERIMENTAL
Intervention: Cobalt-chromium everolimus-eluting stents (CoCr-EES)
Number of subjects: 6645

Group type: EXPERIMENTAL
Intervention: Resolute zotarolimus-eluting stents (Re-ZES)
Number of subjects: 6645

Group type: EXPERIMENTAL
Intervention: Platinum-chromium EES (PtCr-EES)
Number of subjects: 6645

Group type: EXPERIMENTAL
Intervention: Bioresorbable polymer SES (BP-SES)
Number of subjects: 6645

Group type: EXPERIMENTAL
Intervention: Ultrathin strut biodegradable-polymer sirolimus-eluting stents (UT-SES)
Number of subjects: 6645
Study: 36339121

Group type: EXPERIMENTAL
Intervention: Novel shellac plus vitamin E-based DCB
Number of subjects: 82

Group type: COMPARATOR
Intervention: Reference iopromide-based DCB
Number of subjects: 82
Study: 36339124

Group type: EXPERIMENTAL
Intervention: Women (FFR value)
Number of subjects: 655

Group type: COMPARATOR
Intervention: Men (FFR value)
Number of subjects: 655

Group type: EXPERIMENTAL
Intervention: Women (high-risk plaque characteristics)
Number of subjects: 655

Group type: COMPARATOR
Intervention: Men (high-risk plaque characteristics)
Number of subjects: 655

Group type: EXPERIMENTAL
Intervention: Women (myocardial mass)
Number of subjects: 655

Group type: COMPARATOR
Intervention: Men (myocardial mass)
Number of subjects: 655
Study: 36339126

Group type: EXPERIMENTAL
Intervention: Ticagrelor plus aspirin (T+A)
Number of subjects: 405

Group type: COMPARATOR
Intervention: Aspirin alone (A)
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Baseline HbA1c <6.5%
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Baseline HbA1c ≥6.5%
Number of subjects: 405
Study: 36339158

Group type: EXPERIMENTAL
Intervention: Nutrition focused social marketing campaigns
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Modified fishing traps that allow immature fish to escape
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 400
Study: 36339175

Group type: EXPERIMENTAL
Intervention: Post-COVID-19 infected persons
Number of subjects: 547

Group type: COMPARATOR
Intervention: Normative population
Number of subjects: 547

Group type: COMPARATOR
Intervention: Chronic pain patients after spinal surgery
Number of subjects: 547
Study: 36339368

Group type: EXPERIMENTAL
Intervention: Cobalt-chromium everolimus-eluting stents (EES)
Number of subjects: 1450

Group type: EXPERIMENTAL
Intervention: Platinum-chromium everolimus-eluting stents (EES)
Number of subjects: 1450

Group type: EXPERIMENTAL
Intervention: Resolute zotarolimus-eluting stents
Number of subjects: 1450

Group type: EXPERIMENTAL
Intervention: Biodegradable polymer biolimus-eluting stents
Number of subjects: 1450

Group type: COMPARATOR
Intervention: First-generation sirolimus-eluting stents (SES)
Number of subjects: 1450
Study: 36339520

Group type: EXPERIMENTAL
Intervention: Gamification and cognitive control training
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 32
Study: 36339533

Group type: EXPERIMENTAL
Intervention: Compound methyl salicylate liniment (Ammeltz)
Number of subjects: 3600
Study: 36339707

Group type: EXPERIMENTAL
Intervention: Special mountain spa rehabilitation program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of spa rehabilitation with ubiquinol therapy
Number of subjects: 0
Study: 36339849

Group type: EXPERIMENTAL
Intervention: Lifetime PTSD diagnosis
Number of subjects: 79

Group type: COMPARATOR
Intervention: History of trauma
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: PTSD group
Number of subjects: 79

Group type: COMPARATOR
Intervention: Non-PTSD group
Number of subjects: 79
Study: 36339926

Group type: EXPERIMENTAL
Intervention: Savolitinib, a selective MET inhibitor
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Savolitinib
Number of subjects: 66
Study: 36340254

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) with drug-eluting stents
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Comparison of PCI and CABG
Number of subjects: 600
Study: 36340699

Group type: EXPERIMENTAL
Intervention: GUARDIAN socio-technical platform (including Caregiver App, Senior App, and Misty II robot)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GUARDIAN socio-technical platform
Number of subjects: 0
Study: 36341220

Group type: EXPERIMENTAL
Intervention: FI class 2 (0.21-0.31)
Number of subjects: 3881

Group type: EXPERIMENTAL
Intervention: FI class 3 (>0.31)
Number of subjects: 3881

Group type: COMPARATOR
Intervention: FI class 1 (<0.21, nonfrail)
Number of subjects: 3881

Group type: EXPERIMENTAL
Intervention: FI class 2 (0.21-0.31) after multivariable adjustment
Number of subjects: 3881

Group type: EXPERIMENTAL
Intervention: FI class 3 (>0.31) after multivariable adjustment
Number of subjects: 3881
Study: 36341221

Group type: EXPERIMENTAL
Intervention: RD-AVR
Number of subjects: 1020

Group type: COMPARATOR
Intervention: SAVR
Number of subjects: 1020

Group type: COMPARATOR
Intervention: TAVR
Number of subjects: 1020
Study: 36341767

Group type: EXPERIMENTAL
Intervention: Lenvatinib (investigator-assessed mRECIST)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lenvatinib (IRR per mRECIST)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lenvatinib (RECIST v1.1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lenvatinib (investigator-assessed mRECIST) at 2 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lenvatinib (investigator-assessed mRECIST) at 4 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lenvatinib (investigator-assessed mRECIST) at 6 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lenvatinib (multivariate Cox regression analysis)
Number of subjects: 0
Study: 36342102

Group type: EXPERIMENTAL
Intervention: FS118 (800 μg to 0.3 mg/kg followed by 1 to 20 mg/kg weekly)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: FS118 (1 mg/kg or greater)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: FS118
Number of subjects: 43
Study: 36342104

Group type: EXPERIMENTAL
Intervention: Pfizer/BioNTech BNT162b2 or Oxford/AstraZeneca ChAdOx1 vaccine; 99 patients received at least one dose of vaccine prior to, or during the study.
Number of subjects: 152

Group type: COMPARATOR
Intervention: Control group (51 patients who did not receive a vaccination prior to, or during the study).
Number of subjects: 152
Study: 36342109

Group type: EXPERIMENTAL
Intervention: Point-of-care algorithm to stratify patients with acute heart failure according to risk of death, leading to early discharge for low-risk patients (≤3 days) and admission for high-risk patients.
Number of subjects: 5452

Group type: COMPARATOR
Intervention: Usual care (control phase).
Number of subjects: 5452
Study: 36342116

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (30 mg/kg body weight)
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1200
Study: 36342120

Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 1157

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1157
Study: 36342173

Group type: EXPERIMENTAL
Intervention: Surgical revascularization in cohort 1
Number of subjects: 1830

Group type: COMPARATOR
Intervention: Endovascular therapy in cohort 1
Number of subjects: 1830

Group type: EXPERIMENTAL
Intervention: Surgical revascularization in cohort 2
Number of subjects: 1830

Group type: COMPARATOR
Intervention: Endovascular therapy in cohort 2
Number of subjects: 1830
Study: 36342269

Group type: EXPERIMENTAL
Intervention: OCT-detected TCFA
Number of subjects: 390

Group type: COMPARATOR
Intervention: MACE group
Number of subjects: 390
Study: 36342342

Group type: EXPERIMENTAL
Intervention: Adjuvant abemaciclib combined with endocrine therapy (ET)
Number of subjects: 0
Study: 36342343

Group type: EXPERIMENTAL
Intervention: Ketanserin (40 mg p.o.)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 36342421

Group type: EXPERIMENTAL
Intervention: Acute mechanical circulatory support (AMCS)
Number of subjects: 1767

Group type: EXPERIMENTAL
Intervention: De novo HF-CS (DNHF-CS)
Number of subjects: 1767

Group type: COMPARATOR
Intervention: Acute-on-chronic HF-CS
Number of subjects: 1767

Group type: EXPERIMENTAL
Intervention: In-hospital cardiac arrest
Number of subjects: 1767
Study: 36342455

Group type: EXPERIMENTAL
Intervention: mRNA vaccination
Number of subjects: 0
Study: 36342619

Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Eribulin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Capecitabine
Number of subjects: 0
Study: 36342823

Group type: EXPERIMENTAL
Intervention: Notification of primary care clinician and patient regarding incidental CAC, including a patient-specific image of CAC and guideline recommendations for statin use.
Number of subjects: 173

Group type: COMPARATOR
Intervention: Usual care without notification.
Number of subjects: 173
Study: 36342828

Group type: EXPERIMENTAL
Intervention: Digital shared decision-making (SDM) toolkit including a brief animated video, interactive questions, a quiz, a worksheet, and an online guide for clinicians.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 0
Study: 36342853

Group type: EXPERIMENTAL
Intervention: Investigational extended-wear insulin infusion set (IIS)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Conventional Teflon angled insulin infusion set (IIS)
Number of subjects: 6
Study: 36342912

Group type: EXPERIMENTAL
Intervention: Praziquantel (two doses)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 76
Study: 36342964

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 36342972

Group type: EXPERIMENTAL
Intervention: Antidiabetic medications (ADMs) including biguanides (metformin), sulfonylureas (gliclazide, glibenclamide, glimepiride, glipizide, glyclopyramide), insulin (premix, basal, basal/bolus), DPP-4 inhibitors (sitagliptin, vildagliptin, saxagliptin, linagliptin)
Number of subjects: 519

Group type: EXPERIMENTAL
Intervention: DPP-4 inhibitors
Number of subjects: 519
Study: 36343360

Group type: EXPERIMENTAL
Intervention: Raltegravir
Number of subjects: 12
Study: 36343656

Group type: EXPERIMENTAL
Intervention: Hypofractionated preoperative radiotherapy (42.75 Gy in 15 fractions of 2.85 Gy/day for 3 weeks)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Hypofractionated preoperative radiotherapy
Number of subjects: 120
Study: 36343655

Group type: EXPERIMENTAL
Intervention: Diagnostic performance of the intervention (not specified in the abstract)
Number of subjects: 288
Study: 36343674

Group type: COMPARATOR
Intervention: Active Crohn's disease (aCD)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Active ulcerative colitis (aUC)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cutoff values for rectal submucosa in CD
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cutoff values for rectal mucosa in UC
Number of subjects: 60
Study: 36343688

Group type: EXPERIMENTAL
Intervention: High blood eosinophil count (BEC)
Number of subjects: 485

Group type: COMPARATOR
Intervention: Low blood eosinophil count (BEC)
Number of subjects: 485
Study: 36344555

Group type: EXPERIMENTAL
Intervention: Nuclear Transport Checkpoint Inhibitor (NTCI) topical treatment
Number of subjects: 0
Study: 36344663

Group type: EXPERIMENTAL
Intervention: 24 h urinary Na/K ratio of approximately 2
Number of subjects: 1145

Group type: EXPERIMENTAL
Intervention: 24 h urinary Na/K ratio range of 1.6‒2.2 for men
Number of subjects: 1145

Group type: EXPERIMENTAL
Intervention: 24 h urinary Na/K ratio range of 1.7‒1.9 for women
Number of subjects: 1145

Group type: EXPERIMENTAL
Intervention: Average molar ratio of 24 h urinary Na/K was 4.3
Number of subjects: 1145

Group type: EXPERIMENTAL
Intervention: Moderate correlations (P < 0.001) of the 24 h urinary Na/K ratio with 24 h urinary Na and K excretion
Number of subjects: 1145

Group type: EXPERIMENTAL
Intervention: Moderate correlation (P < 0.001) of the 24 h urinary Na/K ratio with dietary Na/K ratio
Number of subjects: 1145
Study: 36344711

Group type: EXPERIMENTAL
Intervention: Nanoliposomal irinotecan (nal-IRI) at 70 mg/m² during HIPEC
Number of subjects: 18
Study: 36344770

Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 1450

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1450
Study: 36344904

Group type: EXPERIMENTAL
Intervention: Male cancer survivors
Number of subjects: 305

Group type: COMPARATOR
Intervention: Female cancer survivors
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Subjects aged 68 or older
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 305
Study: 36344924

Group type: EXPERIMENTAL
Intervention: Cisatracurium 0.15 mg/kg
Number of subjects: 60
Study: 36345016

Group type: EXPERIMENTAL
Intervention: CBT-based mental health app used over five weeks
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: CBT-based mental health app
Number of subjects: 5
Study: 36345143

Group type: EXPERIMENTAL
Intervention: MELD score < 15
Number of subjects: 2826

Group type: EXPERIMENTAL
Intervention: MELD-Na score < 20
Number of subjects: 2826

Group type: COMPARATOR
Intervention: MELD score
Number of subjects: 2826

Group type: COMPARATOR
Intervention: MELD-Na score
Number of subjects: 2826

Group type: COMPARATOR
Intervention: MELD score ≥ 15
Number of subjects: 2826

Group type: COMPARATOR
Intervention: MELD-Na score ≥ 20
Number of subjects: 2826
Study: 36345253

Group type: EXPERIMENTAL
Intervention: RYGB
Number of subjects: 40

Group type: COMPARATOR
Intervention: SG
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nonobese volunteers
Number of subjects: 40
Study: 36345941

Group type: EXPERIMENTAL
Intervention: anti-HIV duoCAR T cells
Number of subjects: 0
Study: 36346005

Group type: EXPERIMENTAL
Intervention: Educational interventions (face-to-face or e-learning focusing on infective area, basic gestures, COVID clinical management and intensive care medicine)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Educational interventions
Number of subjects: 37
Study: 36346044

Group type: EXPERIMENTAL
Intervention: Docetaxel and fluorouracil (infusional fluorouracil of 200 mg/m2)
Number of subjects: 0
Study: 36346059

Group type: EXPERIMENTAL
Intervention: Bleeding Academic Research Consortium 2, 3, or 5 bleeding
Number of subjects: 10364

Group type: EXPERIMENTAL
Intervention: Gastrointestinal bleeding
Number of subjects: 10364

Group type: EXPERIMENTAL
Intervention: Genitourinary bleeding
Number of subjects: 10364

Group type: EXPERIMENTAL
Intervention: New gastrointestinal cancer diagnosis after gastrointestinal bleeding
Number of subjects: 10364

Group type: EXPERIMENTAL
Intervention: New genitourinary cancer diagnosis after genitourinary bleeding
Number of subjects: 10364

Group type: COMPARATOR
Intervention: New cancer diagnosis without previous bleeding
Number of subjects: 10364
Study: 36346112

Group type: EXPERIMENTAL
Intervention: Antidepressant use at baseline
Number of subjects: 1700

Group type: EXPERIMENTAL
Intervention: Antidepressant use at the start of maintenance therapy
Number of subjects: 1700

Group type: EXPERIMENTAL
Intervention: Antidepressant use at the start of maintenance cycle 4
Number of subjects: 1700

Group type: EXPERIMENTAL
Intervention: Antidepressant use at the start of maintenance treatment
Number of subjects: 1700
Study: 36346118

Group type: EXPERIMENTAL
Intervention: FIT with a positivity threshold of >15 mcg haemoglobin/g faeces, interval between rounds varied between 1.5 and 3.5 years
Number of subjects: 0
Study: 36346229

Group type: EXPERIMENTAL
Intervention: Islatravir 60 mg administered orally
Number of subjects: 0
Study: 36346366

Group type: EXPERIMENTAL
Intervention: ERK-MAPK inhibitor (ulixertinib) in combination with CDK4/6 inhibitor (palbociclib)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CRISPR-Cas9 loss-of-function screen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel therapeutic combinations validated using siRNA and small-molecule inhibitors
Number of subjects: 0
Study: 36346472

Group type: EXPERIMENTAL
Intervention: Self-selected meal (SSM)
Number of subjects: 19
Study: 36346679

Group type: EXPERIMENTAL
Intervention: Integrative medicine (IM) intervention, single 30-minute session combining acupuncture, mind-body, and/or manual-movement modalities.
Number of subjects: 114
Study: 36346687

Group type: EXPERIMENTAL
Intervention: Capecitabine
Number of subjects: 658

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 658
Study: 36347049

Group type: COMPARATOR
Intervention: Growth hormone (GH) treatment for 2 years
Number of subjects: 0

Group type: COMPARATOR
Intervention: Growth hormone (GH) treatment for 7 years
Number of subjects: 0
Study: 36347128

Group type: EXPERIMENTAL
Intervention: Endovascular techniques for treatment of ALI
Number of subjects: 0
Study: 36347310

Group type: EXPERIMENTAL
Intervention: User-controlled sperm concentration test
Number of subjects: 38
Study: 36347845

Group type: EXPERIMENTAL
Intervention: Escitalopram (10-20 mg)
Number of subjects: 92
Study: 36347863

Group type: EXPERIMENTAL
Intervention: Neuroprosthesis using deep-learning and language-modeling techniques to decode letter sequences from silent attempts to spell
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Offline simulations of the neuroprosthesis
Number of subjects: 1
Study: 36347900

Group type: EXPERIMENTAL
Intervention: Robotic-assisted partial nephrectomy (RPN)
Number of subjects: 2005

Group type: COMPARATOR
Intervention: Open partial nephrectomy (OPN)
Number of subjects: 2005
Study: 36348054

Group type: EXPERIMENTAL
Intervention: 24-h cough frequency measured using an ambulatory cough monitor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 24-h cough frequency
Number of subjects: 0
Study: 36348206

Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) using cisplatin with mitomycin C
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC)
Number of subjects: 41
Study: 36348245

Group type: EXPERIMENTAL
Intervention: Tafamidis
Number of subjects: 0
Study: 36348346

Group type: EXPERIMENTAL
Intervention: Supportive oncology clinical trial strategies implemented during the COVID-19 pandemic
Number of subjects: 0
Study: 36348974

Group type: EXPERIMENTAL
Intervention: AI system predicting MCI/mild AD
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: AI system predicting Aβ positivity
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: AI system predicting Aβ in MCI/mild AD subsample
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: AI system predicting Aβ in CU subsample
Number of subjects: 133
Study: 36349057

Group type: EXPERIMENTAL
Intervention: Anemia group
Number of subjects: 149

Group type: COMPARATOR
Intervention: Non-anemia group
Number of subjects: 149
Study: 36349343

Group type: EXPERIMENTAL
Intervention: SCFA-producing gut microbes
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Fecal propionate
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Fecal SCFAs
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Glycated hemoglobin (HbA1c)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: DXA and anthropometrics (BMI)
Number of subjects: 45
Study: 36349793

Group type: EXPERIMENTAL
Intervention: Triple combination therapy
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: Rapid decliners
Number of subjects: 518

Group type: COMPARATOR
Intervention: Non-rapid decliners
Number of subjects: 518
Study: 36350017

Group type: EXPERIMENTAL
Intervention: M2SR 108 TCID50
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: M2SR 109 TCID50
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: M2SR
Number of subjects: 0

Group type: COMPARATOR
Intervention: FluMist
Number of subjects: 0
Study: 36350312

Group type: EXPERIMENTAL
Intervention: Molibresib 75 mg daily for MDS
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Molibresib 60 mg daily for CTCL
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Total study population with Molibresib
Number of subjects: 111